

<b>List Funding Source, Project Title &amp; Number</b>	<b>Role In Project</b>	<b>Dates</b>
MH46957/ NIMH Serotonin function in treatment refractory schizophrenia	PI	1990-1991
64766/0207 Janssen Research Foundation, "Risperidone in the treatment of the negative symptoms of schizophrenia"	PI	1992-1993
64766/0208 Janssen Research Foundation, "Risperidone in the treatment of chronic schizophrenia"	PI	1992-1993
Stanley Foundation. The Dutch hunger winter and schizophrenia	Co-PI	1994-199
Solvay. Development of functional MRI	PI	1995-1999
Stanley Foundation. Incidence of psychotic illness in ethnic groups in the Hague	Co-PI	1996-1998
NWO (Dutch Science Organization). A multicenter study on neurobiological and neuropsychological predictors of functional status in first-onset schizophrenia: social disabilities, burden on the family, needs for care and quality of life	Co-PI	1996-2000
NWO (Dutch Science Organization). The neurodynamics of schizophrenia: correlates and functional consequences	Co-PI	1999-2004
Stanley Foundation. Structural brain abnormalities in relation to genotype and environment	Co-PI	1999-2001
Universitair Medisch Centrum Utrecht. Development of a high-throughput system for the genetic dissection of "complex" trait through association analysis, with the emphasis on specific psychiatric disorders	PI	1999-2002
NWO (Dutch Science Organization). Prevention of iatrogenic neurological impairment in schizophrenia: the Schizophrenia Termination of Pharmacotherapy (STOP)-trial	PI	2001-2003
Stanley Center Grant	Co-PI	2001-2004
NWO (Dutch Science Organization). Prediction and prevention of psychosis in youngsters entering regional institutions for ambulatory mental health care institutions	Co-investigator	2002-2005
NWO (Dutch Science Organization). Cognition. Quantitative genetic modelling of variation in cognitive brain maturation: A longitudinal study in pre-adolescent twins.	Co-PI	2001-2004
Effect of olanzapine and ziprazidone on cognition in first-episode schizophrenia	PI	2002-2005
European Group for Research in Schizophrenia. European First Episode Schizophrenia Trial (Eufest)	PI	2002-2006
BMS: Aripiprazole in social cognition	PI	2005-2007
AstraZeneca, Janssen-Cilag, Lilly, Additional support for Vulnerability and resilience in first episode psychosis	PI	2005-2010
TI Pharma – A translational pharmacogenomics approach to improve drugdevelopment strategies for psychiatric disorders	PI	2006-2010
EU 035978-1 MARIE CURIE Research Training Network, European Twin Study network onSchizophrenia (EUTwinsS)	Co-PI	2007-2011

NIMH (1R01MH078075) High-density Genome-wide Association Study inSchizophrenia	Co-PI	2006-2010
NWO (Dutch Science Organization) Project:100001001. Vulnerability and resilience in first episodepsychosis	PI	2003-2013
NWO (Dutch Science Organization) TOP grant 40-00812-98-08018 Determinants of the development of bipolar disorder: two follow-up studies	Co-PI	2009-2013
NIH/NIMH (1R01 MH090553) Genomic studies of bipolar disorder in a large Cohort from The Netherlands	Co-PI	2010-2015
KP7 242114 EU 7th Framework Program. Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)	PI	2010-2016
ZonMw (R2895) NBB-Psy (Netherlands Brain Bank for Psychiatry) Brain matters: Development of the Netherlands Psychiatric Tissue Program (NPTP)	Co-PI	2012-2017
NWO (Dutch Science Organization) TOP: Inflammation in schizophrenia. Project: 40-00812-98-12154	PI	2012-2016
Stanley Foundation Prednisolone augmentation for patients with recent onset schizophrenia	PI	2013-2017
Stanley Foundation. Simvastatin augmentation for recent onset schizophrenia	PI	2013-2017